Open company graph database — free web & API
Login

ReproCell Co., Ltd.

株式会社リプロセルReproCELL Inc.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
101
Related companies
14
§01

Basic information

BASIC
Head office
9th floor, MetLife Shin-Yokohama Building, 8-11 Shin-Yokohama 3-chome, Kōhoku-ku, Yokohama, Kanagawa Prefecture
Chief executive
Shuichi Yokoyama
Capital
2,720,000,000  (27 100 million)
Employees (non-consolidated)
28 people
Employees (consolidated)
101 people
Start date
2003-02-26
End date
§02

Websites

1 DOMAINS
§03

Business

5
Research reagents, equipment, and servicesContracted clinical-grade iPS cells and cell processingRegenerative medicine productsiPS exosomesClinical testing and mail-in testing services
§04

Related companies

14 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Bioserve Biotechnologies India Pvt. Ltd.
Group Subsidiary
REPROCELL Europe Ltd.
Group Subsidiary
Steminent Biotherapeutics Inc.
Group
Biopta
Group
REPROCELL USA Inc.
Group Subsidiary
Personal iPS
Group
BioServe
Group
Cell Innovation Partners
Group
REPROCELL INDIA
Group
Reinnervate
Group
Stemgent
Group
Steminent社
Group
Keio University
Group
株式会社MAGiQセラピューティクス
Group
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

34 EVENTS

ReproCell Co., Ltd. was established as a regenerative medicine venture originating from Kyoto University and the University of Tokyo.Sources

ReproCell Co., Ltd. was established in 2003 as a regenerative medicine venture originating from Kyoto University and the University of Tokyo.Sources

ReproCell Co., Ltd. established.Sources

Started sales of Primate ES cell medium for ES cell culture.Sources

Registered as a sanitary inspection laboratory and began contract clinical testing services.Sources

Used Primate ES cell medium to establish the world's first human iPS cell line.Sources

Established ReproCELL USA.Sources

It went public in its 10th year of operation.Sources

Listed on JASDAQ.Sources

Established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd., focusing on next-generation drug discovery and medical business.Sources

In February 2014, established the venture capital fund 'Cell Innovation Partners' jointly with New Enterprise Investment Co., Ltd.Sources

Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment Co., Ltd.Sources

Established the venture capital fund 'Cell Innovation Partners' in collaboration with New Enterprise Investment.Sources

Acquired Reinnervate (UK) as a subsidiary.Sources

In July 2014, acquired Reinnervate (UK) as a subsidiary.Sources

Acquired Reinnervate (UK) as a subsidiary.Sources

Acquired BioServe (USA) as a subsidiary.Sources

Acquired Stemgent (USA)'s iPS cell business unit and renamed the subsidiary to Stemgent.Sources

Acquired Stemgent (USA)'s iPS cell business unit.Sources

Acquired Biopta (UK) as a subsidiary.Sources

Two UK subsidiaries merged and changed their name to REPROCELL EUROPE.Sources

Two US subsidiaries merged and changed their name to REPROCELL USA.Sources

Acquired Bioserve India (REPROCELL INDIA) as a subsidiary.Sources

In April 2018, acquired Bioserve India (REPROCELL INDIA) as a subsidiary.Sources

Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan.Sources

Established the joint venture 'MAGiQ Therapeutics Co., Ltd.' with Q Therapeutics Inc. (USA) in Japan and began developing regenerative medicine products utilizing iPS cell-derived glial progenitor cells.Sources

Opened the Reprocell Regenerative Medicine Center in Tonemachi.Sources

Acquired Bioserve India as a subsidiary (REPROCELL INDIA).Sources

Commenced clinical trials of the regenerative medicine product StemKaimar®.Sources

Launched the personal iPS cell production and storage service 'Personal iPS'.Sources

Commenced administration to the first subject in Phase II clinical trials and completed the trial in May 2022.Sources

Obtained a 'Special Cell Processing Product Manufacturing Permit' from the Ministry of Health, Labour and Welfare Kanto Shinetsu Health Bureau.Sources

Launched the personal iPS cell production and storage service 'Personal iPS'.Sources

Completion of Phase II clinical trials.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information2020001086778
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社リプロセル
Trade name (kana)
リプロセル
Name in English
Corporation type
301
Address
〒222-0033 神奈川県横浜市港北区新横浜3丁目8番11号
Postal code
2220033
Prefecture code
14
City code
109
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-10-03
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
2657151
METI gBizINFO2020001086778
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
2020001086778
Trade name
株式会社リプロセル
Trade name (kana)
リプロセル
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
神奈川県横浜市港北区新横浜3丁目8番11号
Postal code
2220033
Prefecture
神奈川県
Prefecture code
14
City or district
横浜市港北区
City code
109
Street address
新横浜3丁目8番11号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長 横山 周史
Capital
2720149000
Employees
30
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-10-03
Key information
2020001086778
§09

Sources & updates

SOURCES
↑